130 related articles for article (PubMed ID: 37545027)
1. Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment.
Zhang J; Wang Y; Wang L; You L; Zhang T
Chin Med J (Engl); 2024 Feb; 137(4):408-420. PubMed ID: 37545027
[TBL] [Abstract][Full Text] [Related]
2. Barriers and opportunities for gemcitabine in pancreatic cancer therapy.
Beutel AK; Halbrook CJ
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C540-C552. PubMed ID: 36571444
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Binenbaum Y; Na'ara S; Gil Z
Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
[TBL] [Abstract][Full Text] [Related]
4. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
5. CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells.
Clarke WR; Amundadottir L; James MA
Int J Cancer; 2019 Mar; 144(6):1367-1378. PubMed ID: 30468251
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
7. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Cui QC; Shi J; Wang TX; You L; Shu H
World J Surg; 2013 Jul; 37(7):1688-94. PubMed ID: 23568245
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
9. LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.
Zhu YX; Li CH; Li G; Feng H; Xia T; Wong CH; Fung FKC; Tong JH; To KF; Chen R; Chen Y
Cell Mol Gastroenterol Hepatol; 2020; 10(4):811-828. PubMed ID: 32615164
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
11. EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer.
Yang Z; Chen F; Wei D; Chen F; Jiang H; Qin S
BMC Cancer; 2024 Feb; 24(1):268. PubMed ID: 38408959
[TBL] [Abstract][Full Text] [Related]
12. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.
Tuerhong A; Xu J; Shi S; Tan Z; Meng Q; Hua J; Liu J; Zhang B; Wang W; Yu X; Liang C
Cell Mol Life Sci; 2021 Jul; 78(14):5505-5526. PubMed ID: 34131808
[TBL] [Abstract][Full Text] [Related]
13. CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer.
Zhou Y; Zheng M; Liu Z; Yang H; Zhu P; Jiang JL; Tang J; Chen ZN
Biochem Biophys Res Commun; 2020 Jul; 528(1):62-70. PubMed ID: 32456796
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer.
Park SJ; Yoo HC; Ahn E; Luo E; Kim Y; Sung Y; Yu YC; Kim K; Min DS; Lee HS; Hwang GS; Ahn T; Choi J; Bang S; Han JM
Cancer Res; 2023 Mar; 83(5):735-752. PubMed ID: 36594876
[TBL] [Abstract][Full Text] [Related]
15. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
16. An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma.
Zhang T; Gu Z; Ni R; Wang X; Jiang Q; Tao R
Front Biosci (Landmark Ed); 2023 Dec; 28(12):361. PubMed ID: 38179740
[TBL] [Abstract][Full Text] [Related]
17. Chemoresistance in Pancreatic Cancer.
Zeng S; Pöttler M; Lan B; Grützmann R; Pilarsky C; Yang H
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514451
[TBL] [Abstract][Full Text] [Related]
18. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
Luo W; Yang G; Qiu J; Luan J; Zhang Y; You L; Feng M; Zhao F; Liu Y; Cao Z; Zheng L; Zhang T; Zhao Y
Cancer Med; 2019 Oct; 8(14):6403-6413. PubMed ID: 31475468
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
20. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
